Literature DB >> 11518477

Epidemiology of prescriptions for neuroleptic drugs: tranquilizers rather than antipsychotics.

M Linden1, C Thiels.   

Abstract

BACKGROUND: The pharmacology of neuroleptics as well as epidemiological and clinical observations of prescriptions of these drugs give the impression that they are and can be used for indications other than schizophrenia to a considerable degree.
METHOD: We analyzed pharmacoepidemiological data on neuroleptic prescriptions in Germany. We used the following criteria: numbers of defined daily doses (DDDs) per annum, diagnoses for which they were prescribed, patient age, specialist medical training of the prescribing physician, and indicators that neuroleptics were used instead of other psychotropic drugs such as minor tranquilizers.
RESULTS: Only 14% of the prescriptions for neuroleptic drugs were for schizophrenic psychoses, 18% for other paranoid psychoses and 5% for affective disorders. 63% were prescribed for neurotic disorders, sleep disorders, or dementia. Almost half of the neuroleptic prescriptions were given for patients aged 65 years or over. Only 40% were prescribed by psychiatrists or neurologists. Throughout the period from 1986 to 1995, neuroleptic prescriptions increased steadily, which was paralleled by a decrease in the prescription rates for benzodiazepines.
CONCLUSIONS: Evaluation is urgently needed for those uses of neuroleptic drugs that, from a pharmacoepidemiological perspective, must be seen as their primary indication.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11518477     DOI: 10.1055/s-2001-15880

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  10 in total

1.  Use of psychotropics is high among very old people.

Authors:  Sirpa Hartikainen; Timo Klaukka
Journal:  Eur J Clin Pharmacol       Date:  2003-12-02       Impact factor: 2.953

Review 2.  Interactions between psychotropics, anaesthetics and electroconvulsive therapy: implications for drug choice and patient management.

Authors:  Mohamed Naguib; Robert Koorn
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 3.  Antipsychotic-induced hyponatraemia: a systematic review of the published evidence.

Authors:  Didier Meulendijks; Cyndie K Mannesse; Paul A F Jansen; Rob J van Marum; Toine C G Egberts
Journal:  Drug Saf       Date:  2010-02-01       Impact factor: 5.606

4.  Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression.

Authors:  Laura Gedge; Lauren Lazowski; David Murray; Ruzica Jokic; Roumen Milev
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

Review 5.  Sleep disturbances in patients with schizophrenia : impact and effect of antipsychotics.

Authors:  Stefan Cohrs
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

6.  Use of second-generation antipsychotic agents for sleep and sedation: a provider survey.

Authors:  Eric D A Hermes; Michael Sernyak; Robert Rosenheck
Journal:  Sleep       Date:  2013-04-01       Impact factor: 5.849

7.  The pharmacological treatment of schizophrenia in Chinese patients: a comparison of prescription patterns between 1996 and 1999.

Authors:  Gabor S Ungvari; Yiu Gar Chung; Yip Ka Chee; Ng Fung-Shing; Tang Wai Kwong; Helen F K Chiu
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335

8.  Sleep-promoting properties of quetiapine in healthy subjects.

Authors:  Stefan Cohrs; Andrea Rodenbeck; Zhenghua Guan; Kathrin Pohlmann; Wolfgang Jordan; Andreas Meier; Eckart Rüther
Journal:  Psychopharmacology (Berl)       Date:  2004-03-17       Impact factor: 4.530

9.  Primary care use of antipsychotic drugs: an audit and intervention study.

Authors:  Ann M Mortimer; Charles J Shepherd; Michael Rymer; Alison Burrows
Journal:  Ann Gen Psychiatry       Date:  2005-11-29       Impact factor: 3.455

Review 10.  Social inequality, scientific inequality, and the future of mental illness.

Authors:  Charles E Dean
Journal:  Philos Ethics Humanit Med       Date:  2017-12-19       Impact factor: 2.464

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.